Figure 3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

Gene mutations by race. A, Percentage of tumors from Black versus White patients that are positive for the indicated gene mutations. #, P < 0.001; ns, not significant. B–E, Probability of Black patients having a TP53 (B), APC (C), KRAS (D), or PIK3CA (E) mutation relative to White patients for each individual tumor type. *, P < 0.05; #, P < 0.001. When data are not shown, we did not produce confidence intervals because of low gene mutation prevalence for the indicated cancer type.